VYCO files Item 2.02 8-K with Q3 and YTD 2025 results

Rhea-AI Filing Summary

Vycor Medical, Inc. furnished an Item 2.02 report announcing a press release with financial results for the three and nine months ended September 30, 2025.

The release includes non-GAAP measures—Cash Operating Expenses and Cash Operating Loss—which exclude Depreciation and non-cash Stock Compensation, with reconciliations to comparable GAAP measures. The press release is attached as Exhibit 99.1, and the information is furnished and not deemed “filed” under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001424768 0001424768 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2025

Vycor Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-34932		20-3369218
(State or Other Jurisdiction of Incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

951 Broken Sound Parkway, Suite 320, Boca Raton, FL		33487
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (561) 558-2020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock		VYCO		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

TABLE OF CONTENTS

Item 2.02.	Results of Operations and Financial Conditions
Item 9.01	Financial Statements and Exhibits
SIGNATURES

Item 2.02. Results of Operations and Financial Conditions

The information in this report and the exhibit attached hereto are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act of 1934 or the Securities Act of 1933, except as shall be expressly set forth by specific reference to such filing.

On November 14, 2025, we issued a press release regarding our financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Non-GAAP Measures

We make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures that exclude Depreciation and non-cash Stock Compensation.

We believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1.		Vycor Medical, Inc. Press Release dated November 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vycor Medical, Inc.
By:	/s/ Peter C. Zachariou
Name:	Peter C. Zachariou
Title:	Chief Executive Officer
Dated:	November 14, 2025

FAQ

What did VYCO disclose in its 8-K?

Vycor Medical furnished a press release with financial results for the three and nine months ended September 30, 2025 under Item 2.02.

Which non-GAAP metrics does VYCO highlight?

The press release discusses non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss, excluding Depreciation and non-cash Stock Compensation, with GAAP reconciliations.

Where can I find the detailed results?

They are provided in Exhibit 99.1, the press release furnished with the report.

Is the information considered "filed" with the SEC?

No. It is furnished under Item 2.02 and not deemed “filed” for purposes of Section 18 of the Exchange Act.

What period does the press release cover?

The three and nine months ended September 30, 2025.

What is Vycor Medical’s trading symbol and market?

The common stock trades under the symbol VYCO on the OTCQB.